When the Trial Fails, Was It the Drug or the Design?
NetraMark's Chief Innovation and Regulatory Officer Luca Pani, MD, on why broad enrollment can obscure treatment effects, what makes...
AbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancer
Daejin Abidoye, Vice President, Therapeutic Area Head, Oncology, Solid Tumor and Hematology at AbbVie, discusses new data from ABBV-1480...
What the Lancet Psychiatry Mania Data Gets Right, and What It Still Can’t Tell Us
A new target trial emulation in Lancet Psychiatry challenges antipsychotic-first strategies in early psychotic mania. Here's what it means...
Velocity Clinical Research appoints Justin Starzyk as CEO
Velocity Clinical Research appoints Justin Starzyk as CEO to lead its 70+ research sites across the U.S. and Europe.
Teva Study: Providers Prioritize Tolerability Over Efficacy in Tardive Dyskinesia
Teva study reveals healthcare providers prioritize tolerability and dosing convenience over efficacy when treating tardive dyskinesia in older patients.
Teva’s TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trial
TEV-749 olanzapine LAI achieved 80% clinical stabilization in schizophrenia patients during the SOLARIS Phase 3 trial, with durability sustained...
CHMP Recommends Ocrevus Approval for Pediatric Relapsing MS
CHMP recommends Ocrevus pediatric relapsing MS approval for children aged 10+, advancing toward European Commission authorization within two months.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer
FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer, doubling progression-free survival in Phase 3 trials.
The RIO Trial’s Viral Rebound Data Just Complicated Every HIV Functional Cure Strategy on the Market
Phase 2 RIO trial shows 3BNC117-LS and 10-1074-LS delay HIV viral rebound after treatment interruption, but resistance patterns raise...
Certara Launches External Data Accelerator for CDISC Standards Compliance
Certara launches External Data Accelerator to catch vendor data conformance issues before submission, addressing 70% of clinical study data...